Acorda Therapeutics, Inc.

ACOR.Q

US00484M7002

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 03:30:00 21/06/2024 am IST			5-day change	1st Jan Change
0.2783 ^USD	+9.14%		+11.32%	-98.16%

12/06	Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	CI
14/05	Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index

April 05, 2024

Latest news about Acorda Therapeutics, Inc.

Motion for Asset Sale Approved for Acorda Therapeutics, Inc.	12/06	CI
Acorda Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Liquidation Plan and Disclosure Statement Filed by Acorda Therapeutics, Inc.	10/05	CI
Final DIP Financing Approved for Acorda Therapeutics, Inc.	03/05	CI
Bidding Procedure Approved for Acorda Therapeutics, Inc.	29/04	CI
Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market	16/04	MT
Interim DIP Financing Approved for Acorda Therapeutics, Inc.	05/04	CI
Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from S&P TMI Index	05/04	CI
Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.	01/04	CI
Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023	09/23/09

Chart Acorda Therapeutics, Inc.

Duration

Period

More charts

Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinsonâs disease treated with carbidopa/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACORDA THERAPEUTICS, INC.	-98.16%	346K
VERTEX PHARMACEUTICALS INCORPORATED	+15.19%	121B
REGENERON PHARMACEUTICALS, INC.	+19.91%	114B
BIONTECH SE	-19.80%	20.43B
GENMAB A/S	-15.87%	16.55B
BEIGENE, LTD.	-13.45%	16.45B
WUXI APPTEC CO., LTD.	-44.35%	15.59B
SAREPTA THERAPEUTICS, INC.	+66.67%	15.19B
NEUROCRINE BIOSCIENCES, INC.	+2.13%	13.54B
INSMED INCORPORATED	+119.39%	10.96B